港股詳情

本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

醫藥外包概念

1,793.042

+20.8101.17%

漲家數：4

跌家數：4

平家數：- -

市盈率：- -

高：1,835.570

開：1,770.415

低：1,747.549

收：1,772.232

資料載入中...

泰格醫藥(300347.SZ)已耗資約5億元回購股份980.63萬股

滬深300製藥與生物科技指數報7436.24點，前十大權重包含藥明康德等

江蘇恩華藥業股份有限公司藥品申請臨牀試驗默示許可獲受理

阿斯利康全球研發（中國）有限公司藥品申請臨牀試驗默示許可獲受理

杭州博之鋭生物製藥有限公司藥品申請臨牀試驗默示許可獲受理

浙江海昶生物醫藥技術有限公司藥品申請臨牀試驗默示許可獲受理

昭衍新藥盤中異動早盤大幅拉昇5.14%

基石藥業PD-1/VEGF/CTLA-4三抗CS2009全球多中心I期臨牀試驗完成首例患者給藥

每日经济新闻

港股異動 | 來凱醫藥-B(02105)再漲近5% 公司自研新藥LAE120獲美國FDA臨牀試驗批准

智通财经网

聯邦制藥附屬公司創新藥UBT251注射液獲FDA批准開展II期臨牀試驗

藥明生物(02269.HK)推全新微生物表達平臺EffiX

阿斯达克财经

基石藥業(02616.HK)治療實體瘤藥物臨牀試驗順利完成首例患者給藥

阿斯达克财经

藥明生物推出全新微生物表達平臺EffiX

基石藥業(02616)CS2009全球多中心I期臨牀試驗完成首例患者給藥

【基石藥業-B(02616.HK)：PD-1/VEGF/CTLA-4三特異性抗體CS2009全球多中心I期臨牀試驗順利完成首例患者給藥】基石藥業-B(02616.HK)發佈公告，公司自主研發的PD-1/VEGF/CTLA-4三特異性抗體CS2009的全球多中心I期臨牀試驗順利完成首例患者給藥，未發生輸液反應或其他不良事件。

基石藥業-B(02616)：PD-1/VEGF/CTLA-4三特異性抗體CS2009全球多中心I期臨牀試驗順利完成首例患者給藥

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/BK1576/news?page=5"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK1576"},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1576\",,,,,undefined,":{"symbol":"BK1576","market":"HK","secType":"PLATE","nameCN":"醫藥外包概念","latestPrice":1793.0419,"timestamp":1741334919514,"preClose":1772.232,"halted":0,"volume":105965997,"delay":0,"changeRate":0.011742,"change":20.809814,"pbRate":2.648404,"amount":2334342230,"amplitude":0.049667,"prevYearClose":1395.7731,"fiveDayClose":1699.456,"twentyDayClose":1588.191,"turnoverRate":0.008873,"marketCap":381645564416,"floatMarketCap":165840598400,"peRate":33.012456},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1576\",,,,,undefined,":{"symbol":"BK1576","high":1835.5696,"amplitude":0.049667,"preClose":1772.232,"low":1747.5487,"pbRate":"2.648404","latestPrice":1793.0419,"volume":105965997,"delay":0,"open":1770.415,"prevYearClose":1395.7731,"prevWeekClose":1699.456,"prevMonthClose":1699.456,"prevQuarterClose":1395.773,"fiveDayClose":1699.456,"twentyDayClose":1588.191,"sixtyDayClose":1337.64,"secType":"PLATE","market":"HK","turnoverRate":0.008873,"peRate":33.012456,"marketCap":381645564416,"floatMarketCap":165840598400,"timestamp":1741334919514,"nameCN":"醫藥外包概念"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1576\",,,,undefined,":{"bkCode":"BK1576","up":4,"down":4,"flat":0},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1576\",pageSize:16,pageCount:5,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2516408506","title":"泰格醫藥(300347.SZ)已耗資約5億元回購股份980.63萬股","url":"https://stock-news.laohu8.com/highlight/detail?id=2516408506","media":"智通财经","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516408506?lang=zh_tw&edition=fundamental","pubTime":"2025-03-04 16:48","pubTimestamp":1741078111,"startTime":"0","endTime":"0","summary":"智通财经APP讯，泰格医药(300347.SZ)发布公告，截至2025年2月28日，公司股份回购专用证券账户以集中竞价交易方式累计回购公司股份980.63万股，占公司总股本的比例为1.1337%，占公司A股总股本比例为1.3219%，最高成交价为62.00元/股，最低成交价为48.17元/股，成交总金额为5亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1257502.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1576","LU1820825898.SGD","BK1583","BK0077","03347","BK0174","BK0028","LU1146622755.USD","300347","BK1141","BK0216"],"gpt_icon":0},{"id":"2516459226","title":"滬深300製藥與生物科技指數報7436.24點，前十大權重包含藥明康德等","url":"https://stock-news.laohu8.com/highlight/detail?id=2516459226","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516459226?lang=zh_tw&edition=fundamental","pubTime":"2025-03-04 15:19","pubTimestamp":1741072746,"startTime":"0","endTime":"0","summary":"数据统计显示，沪深300制药与生物科技指数近一个月上涨3.05%，近三个月下跌4.64%，年至今下跌0.11%。沪深300行业指数系列分别以进入各一级、二级、三级、四级行业的全部证券作为样本编制指数，形成沪深300行业指数。从沪深300制药与生物科技指数持仓样本的行业来看，化学药占比39.69%、制药与生物科技服务占比23.21%、中药占比19.52%、生物药品占比17.58%。在样本公司有特殊事件发生，导致其行业归属发生变更时，将对沪深300行业指数样本进行相应调整。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/03/04151948506040.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["LU0052750758.USD","LU0708995583.HKD","LU2125910500.SGD","LU2045819591.USD","02359","000001.SH","BK1191","BK1576","LU1046422090.SGD","LU1997245177.USD","LU1997245094.SGD","CHAD","399300","159919","BK1583","CHAU","BK1141","159837","01477","BK1574","BK0216","LU2242644610.SGD","LU0320764599.SGD","LU0456842615.SGD","603259","LU2488822045.USD"],"gpt_icon":0},{"id":"2516712616","title":"江蘇恩華藥業股份有限公司藥品申請臨牀試驗默示許可獲受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2516712616","media":"金融界","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516712616?lang=zh_tw&edition=fundamental","pubTime":"2025-03-04 12:18","pubTimestamp":1741061880,"startTime":"0","endTime":"0","summary":"3月4日，据CDE官网消息，江苏恩华药业股份有限公司联合申请药品“盐酸他喷他多口服溶液”，获得临床试验默示许可，受理号CYHL2400265。江苏恩华药业股份有限公司，成立于1999年，位于徐州市，是一家以从事医药制造业为主的企业。通过天眼查大数据分析，江苏恩华药业股份有限公司共对外投资了21家企业，参与招投标项目4477次，知识产权方面有商标信息398条，专利信息257条，此外企业还拥有行政许可655个。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/03/04121848504567.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1141","002262","BK0188","BK1576","BK0070","03347","BK1583","BK0239"],"gpt_icon":0},{"id":"2516661606","title":"阿斯利康全球研發（中國）有限公司藥品申請臨牀試驗默示許可獲受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2516661606","media":"金融界","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516661606?lang=zh_tw&edition=fundamental","pubTime":"2025-03-04 12:18","pubTimestamp":1741061880,"startTime":"0","endTime":"0","summary":"3月4日，据CDE官网消息，阿斯利康全球研发（中国）有限公司、阿斯利康制药有限公司、上海合全医药有限公司联合申请药品“Ceralasertib薄膜包衣片”，获得临床试验默示许可，受理号CXHB2400299。阿斯利康全球研发（中国）有限公司，成立于2021年，位于上海市，是一家以从事研究和试验发展为主的企业。主要股东信息显示，阿斯利康全球研发（中国）有限公司由阿斯利康大陆有限公司 ASTRAZENECA CONTINENT B.V.持股100%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/03/04121848504570.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["LU2456880835.USD","BK4588","BK4585","AZN","LU0320765992.SGD","LU2417539215.USD","BK1583","BK4568","LU2462157665.USD","BK1576","BK4007","LU0889565916.HKD","BK1141","03347","LU2236285917.USD","LU1829250122.USD","LU0109394709.USD"],"gpt_icon":0},{"id":"2516167776","title":"杭州博之鋭生物製藥有限公司藥品申請臨牀試驗默示許可獲受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2516167776","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516167776?lang=zh_tw&edition=fundamental","pubTime":"2025-03-04 12:18","pubTimestamp":1741061880,"startTime":"0","endTime":"0","summary":"3月4日，据CDE官网消息，杭州博之锐生物制药有限公司、浙江博锐生物制药有限公司联合申请药品“注射用BR111”，获得临床试验默示许可，受理号CXSL2400885。通过天眼查大数据分析，杭州博之锐生物制药有限公司参与招投标项目279次，知识产权方面有商标信息4条，专利信息37条，此外企业还拥有行政许可32个。主要股东信息显示，杭州博之锐生物制药有限公司由浙江博锐生物制药有限公司持股100%。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/03/04121848504565.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1141","03347","BK1576","BK1583"],"gpt_icon":0},{"id":"2516160536","title":"浙江海昶生物醫藥技術有限公司藥品申請臨牀試驗默示許可獲受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2516160536","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516160536?lang=zh_tw&edition=fundamental","pubTime":"2025-03-04 12:18","pubTimestamp":1741061880,"startTime":"0","endTime":"0","summary":"3月4日，据CDE官网消息，浙江海昶生物医药技术有限公司联合申请药品“HC016脂质复合物注射液”，获得临床试验默示许可，受理号CXHL2401413。浙江海昶生物医药技术有限公司，成立于2013年，位于杭州市，是一家以从事科技推广和应用服务业为主的企业。通过天眼查大数据分析，浙江海昶生物医药技术有限公司共对外投资了6家企业，参与招投标项目59次，知识产权方面有商标信息10条，专利信息18条，此外企业还拥有行政许可18个。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/03/04121848504568.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1141","161726","03347","399441","BK1583","BK1576"],"gpt_icon":0},{"id":"2516690928","title":"昭衍新藥盤中異動 早盤大幅拉昇5.14%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516690928","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516690928?lang=zh_tw&edition=fundamental","pubTime":"2025-03-04 10:45","pubTimestamp":1741056319,"startTime":"0","endTime":"0","summary":"2025年03月04日早盘10时45分，昭衍新药股票出现异动，股价快速拉升5.14%。截至发稿，该股报13.900港元/股，成交量146.078万股，换手率1.23%，振幅8.17%。机构评级方面，在所有6家参与评级的机构中，67%的券商给予买入建议，17%的券商给予持有建议，16%的券商给予卖出建议。昭衍新药股票所在的生物技术行业中，整体跌幅为2.32%。其相关个股中，和誉-B、荃信生物-B、科笛-B涨幅较大，振幅较大的相关个股有科笛-B、北海康成-B、和誉-B，振幅分别为12.21%、12.14%、11.71%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025030410451996386f36&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025030410451996386f36&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1576","06127","BK1141"],"gpt_icon":0},{"id":"2516690737","title":"基石藥業PD-1/VEGF/CTLA-4三抗CS2009全球多中心I期臨牀試驗完成首例患者給藥","url":"https://stock-news.laohu8.com/highlight/detail?id=2516690737","media":"每日经济新闻","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516690737?lang=zh_tw&edition=fundamental","pubTime":"2025-03-04 10:43","pubTimestamp":1741056197,"startTime":"0","endTime":"0","summary":"每经AI快讯，基石药业今日宣布，公司自主研发的PD-1/VEGF/CTLA-4三特异性抗体CS2009的全球多中心I期临床试验顺利完成首例患者给药，未发生输液反应或其他不良事件。该试验将深入评估CS2009在多种晚期实体瘤中的临床应用价值，包括非小细胞肺癌、肝癌、胃癌、子宫内膜癌、卵巢癌、肾细胞癌及宫颈癌等，进而推动肿瘤免疫疗法的创新与发展。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202503043335813894.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202503043335813894.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1576","BK1583","BK4023","03347","LU1169590202.USD","BK1141","LU1169589451.USD","PD"],"gpt_icon":0},{"id":"2516558697","title":"港股異動 | 來凱醫藥-B(02105)再漲近5% 公司自研新藥LAE120獲美國FDA臨牀試驗批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2516558697","media":"智通财经网","labels":["productRelease","movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516558697?lang=zh_tw&edition=fundamental","pubTime":"2025-03-04 10:23","pubTimestamp":1741054980,"startTime":"0","endTime":"0","summary":"来凯医药-B再涨近5%，截至发稿，涨4.85%，报13.4港元，成交额3360.26万港元。消息面上，来凯医药昨日宣布，美国食品药品监督管理局已批准其自主研发的LAE120，一种强效、高选择性USP1抑制剂的新药临床试验申请，用于治疗晚期实体瘤患者。公司表示正积极开展外部合作以加快LAE120临床开发进展。来凯医药首席执行官吕向阳博士表示，来凯又一款早期研发项目获批IND，体现了来凯在新药研发领域的实力。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2025-03-04/doc-inenncvp9980225.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,movement","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["02105","BK1576","BK1161","BK1583","BK1141","03347"],"gpt_icon":0},{"id":"2516912266","title":"聯邦制藥附屬公司創新藥UBT251注射液獲FDA批准開展II期臨牀試驗","url":"https://stock-news.laohu8.com/highlight/detail?id=2516912266","media":"财中社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516912266?lang=zh_tw&edition=fundamental","pubTime":"2025-03-04 09:31","pubTimestamp":1741051903,"startTime":"0","endTime":"0","summary":"3月4日，联邦制药（03933）发布公告，近日公司全资附属公司联邦生物科技（珠海横琴）有限公司自主研发的1类创新药UBT251注射液获得美国药品监督管理局（FDA）批准，允许开展慢性肾脏病（CKD）适应症的II期临床试验。此前，该适应症已于2025年1月20日获得中国国家药品监督管理局的临床试验批准。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202503043335652766.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1141","BK1574","06978","BK1576","BK1191","03347","BK1161","03933","BK1583"],"gpt_icon":0},{"id":"2516699110","title":"藥明生物(02269.HK)推全新微生物表達平臺EffiX","url":"https://stock-news.laohu8.com/highlight/detail?id=2516699110","media":"阿斯达克财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516699110?lang=zh_tw&edition=fundamental","pubTime":"2025-03-04 09:18","pubTimestamp":1741051080,"startTime":"0","endTime":"0","summary":"药明生物宣布推出创新技术平台EffiX，该平台基于大肠杆菌表达系统建立，旨在生产和交付高产量、高稳定性重组蛋白与质粒DNA，通过提供全面且具有成本效益的CMC策略，简化工艺开发流程，可以满足从研究到商业化生产的各种项目服务需求，协助全球合作伙伴加速研发创新生物疗法。","market":"other","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20190401142438853_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20190401142438853_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1421839/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["LU0588546209.SGD","LU0039217434.USD","LU0456827905.SGD","LU0516422952.EUR","SG9999002463.SGD","LU1794554557.SGD","LU0181495838.USD","LU0516422440.USD","LU0052750758.USD","LU0823426480.USD","LU1688375341.USD","SG9999002562.SGD","LU0516423174.USD","LU0819121731.USD","LU2039709279.SGD","LU0348735423.USD","02269","LU0456846285.SGD","LU0359201612.USD","LU0327786744.USD","LU0043850808.USD","LU0979878070.USD","LU1242518857.USD","LU0516422366.SGD","BK1141","LU0307460666.USD","LU0516423091.SGD","LU0572944931.SGD","LU0359202008.SGD","LU0417516738.SGD","BK1521","LU0051755006.USD","LU0417516902.SGD","LU1720050803.USD","BK1576","IE00B0JY6N72.USD","LU0856984785.SGD","BK1589","BK1610","LU0320764599.SGD","LU0348825331.USD","LU0823426308.USD","LU0140636845.USD","LU1880383366.USD","LU1242518931.SGD","LU0326950275.SGD","LU0708995583.HKD"],"gpt_icon":0},{"id":"2516361696","title":"基石藥業(02616.HK)治療實體瘤藥物臨牀試驗順利完成首例患者給藥","url":"https://stock-news.laohu8.com/highlight/detail?id=2516361696","media":"阿斯达克财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516361696?lang=zh_tw&edition=fundamental","pubTime":"2025-03-04 09:00","pubTimestamp":1741050000,"startTime":"0","endTime":"0","summary":"基石药业公布，其自主研发的PD-1/VEGF/CTLA-4三特异性抗体CS2009的全球多中心I期临床试验顺利完成首例患者给药，未发生输液反应或其他不良事件。该试验将深入评估CS2009在多种晚期实体瘤中的临床应用价值，包括非小细胞肺癌、肝癌、胃癌、子宫内膜癌、卵巢癌、肾细胞癌及宫颈癌等，旨在推动创新肿瘤免疫疗法的发展。临床前研究显示，CS2009的抗肿瘤活性优于潜在竞品。(港股报价延迟最少十五分钟。","market":"sh","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20230626115201047_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20230626115201047_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1421823/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1161","BK1141","02616","BK1576","BK1583","BK1574","03347"],"gpt_icon":0},{"id":"2516869507","title":"藥明生物推出全新微生物表達平臺EffiX","url":"https://stock-news.laohu8.com/highlight/detail?id=2516869507","media":"人民财讯","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516869507?lang=zh_tw&edition=fundamental","pubTime":"2025-03-04 08:48","pubTimestamp":1741049328,"startTime":"0","endTime":"0","summary":"【药明生物推出全新微生物表达平台EffiX】药明生物（02269.HK）今日宣布，推出创新技术平台EffiXTM。该平台基于大肠杆菌表达系统建立，旨在生产和交付高产量、高稳定性重组蛋白与质粒DNA。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://hk.eastmoney.com/a/202503043335398947.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0456827905.SGD","LU0516422952.EUR","LU0979878070.USD","BK1610","LU1794554557.SGD","BK1141","LU0823426480.USD","LU0327786744.USD","LU0181495838.USD","LU0359201612.USD","BK1521","LU0856984785.SGD","LU0326950275.SGD","LU0348735423.USD","LU0588546209.SGD","LU0051755006.USD","IE00B0JY6N72.USD","02269","LU0307460666.USD","LU1242518931.SGD","LU0819121731.USD","BK1576","LU0052750758.USD","LU0823426308.USD","LU2039709279.SGD","LU0320764599.SGD","BK1589","SG9999002463.SGD","LU1880383366.USD","LU1242518857.USD","LU0348825331.USD","LU0043850808.USD","LU0456846285.SGD","LU0572944931.SGD","LU0708995583.HKD","LU1720050803.USD","LU0140636845.USD","LU1688375341.USD","LU0516422366.SGD","LU0359202008.SGD","SG9999002562.SGD","LU0516423091.SGD","LU0039217434.USD","LU0516422440.USD","LU0516423174.USD","LU0417516738.SGD","LU0417516902.SGD"],"gpt_icon":0},{"id":"2516269575","title":"基石藥業(02616)CS2009全球多中心I期臨牀試驗完成首例患者給藥","url":"https://stock-news.laohu8.com/highlight/detail?id=2516269575","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516269575?lang=zh_tw&edition=fundamental","pubTime":"2025-03-04 08:47","pubTimestamp":1741049275,"startTime":"0","endTime":"0","summary":"金吾财讯 | 基石药业(02616)公布，公司自主研发的PD-1/VEGF/CTLA-4三特异性抗体CS2009的全球多中心I期临床试验顺利完成首例患者给药，未发生输液反应或其他不良事件。该试验将深入评估CS2009在多种晚期实体瘤中的临床应用价值，包括非小细胞肺癌、肝癌、胃癌、子宫内膜癌、卵巢癌、肾细胞癌及宫颈癌等，旨在推动创新肿瘤免疫疗法的发展。","market":"sh","thumbnail":"https://static.szfiu.com/news/20241108/ZjQ2YTc2OWU5OTg2NTUyNTg4MTk4NA==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/ZjQ2YTc2OWU5OTg2NTUyNTg4MTk4NA==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1954249","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02616","03347","BK1583","BK1161","BK1574","BK1141","BK1576"],"gpt_icon":0},{"id":"2516984776","title":"【基石藥業-B(02616.HK)：PD-1/VEGF/CTLA-4三特異性抗體CS2009全球多中心I期臨牀試驗順利完成首例患者給藥】基石藥業-B(02616.HK)發佈公告，公司自主研發的PD-1/VEGF/CTLA-4三特異性抗體CS2009的全球多中心I期臨牀試驗順利完成首例患者給藥，未發生輸液反應或其他不良事件。","url":"https://stock-news.laohu8.com/highlight/detail?id=2516984776","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516984776?lang=zh_tw&edition=fundamental","pubTime":"2025-03-04 08:10","pubTimestamp":1741047048,"startTime":"0","endTime":"0","summary":"基石药业-B(02616.HK)发布公告，公司自主研发的PD-1/VEGF/CTLA-4三特异性抗体CS2009的全球多中心I期临床试验顺利完成首例患者给药，未发生输液反应或其他不良事件。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/04081048500557.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["LU1169589451.USD","BK4023","BK1141","PD","BK1161","02616","BK1574","03347","BK1576","LU1169590202.USD","BK1583"],"gpt_icon":0},{"id":"2516698610","title":"基石藥業-B(02616)：PD-1/VEGF/CTLA-4三特異性抗體CS2009全球多中心I期臨牀試驗順利完成首例患者給藥","url":"https://stock-news.laohu8.com/highlight/detail?id=2516698610","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516698610?lang=zh_tw&edition=fundamental","pubTime":"2025-03-04 08:06","pubTimestamp":1741046794,"startTime":"0","endTime":"0","summary":"智通财经APP讯，基石药业-B 发布公告，公司自主研发的PD-1/VEGF/CTLA-4三特异性抗体CS2009的全球多中心I期临床试验顺利完成首例患者给药，未发生输液反应或其他不良事件。目前，CS2009率先在澳大利亚开展多中心I期临床试验，未来将陆续扩展至中国及美国。据悉，CS2009是一款靶向PD-1、VEGFA及CTLA-4的三特异性分子，作为靶向大瘤种的三特异性抗体，具备同类首创/同类最优潜力。临床前数据显示，CS2009具有明显优于潜在竞品的抗肿瘤活性。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1257261.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1583","03347","BK1576","BK1161","BK1141","BK1574","LU1169590202.USD","02616","LU1169589451.USD","BK4023","PD"],"gpt_icon":0}],"pageSize":16,"totalPage":14,"pageCount":5,"totalSize":214}]}}